Population pharmacokinetics of vancomycin in obesity: Finding the optimal dose for (morbidly) obese individuals

AIMS: For vancomycin treatment in obese patients, there is no consensus on the optimal dose that will lead to the pharmacodynamic target (area under the curve 400–700 mg h L(−1)). This prospective study quantifies vancomycin pharmacokinetics in morbidly obese and nonobese individuals, in order to gu...

Descripción completa

Detalles Bibliográficos
Autores principales: Smit, Cornelis, Wasmann, Roeland E., Goulooze, Sebastiaan C., Wiezer, Marinus J., van Dongen, Eric P.A., Mouton, Johan W., Brüggemann, Roger J.M., Knibbe, Catherijne A.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7015748/
https://www.ncbi.nlm.nih.gov/pubmed/31661553
http://dx.doi.org/10.1111/bcp.14144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7015748/
https://www.ncbi.nlm.nih.gov/pubmed/31661553
http://dx.doi.org/10.1111/bcp.14144

Ejemplares similares